Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Points to consider-Raynaud's phenomenon in systemic sclerosis.

Maurizio Cutolo1, Vanessa Smith2,3, Daniel E Furst4

  • 1Research Laboratories and Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS, University of Genova, Genova, Italy.

Rheumatology (Oxford, England)
|October 10, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Refining Human Phenotype Ontology (HPO) to enable better phenotype-genotype integration in systemic autoimmune rheumatic diseases.

Orphanet journal of rare diseases·2026
Same author

Identifying candidate core domains for clinical trials in systemic sclerosis-associated Raynaud's phenomenon and digital ulcers.

Seminars in arthritis and rheumatism·2026
Same author

Influence of comorbidities and patient demographics on Raynaud's symptom characteristics: implications for diagnosis and management.

Journal of scleroderma and related disorders·2026
Same author

Novel HLA class I and II insights into the pathogenesis of systemic sclerosis-associated interstitial lung disease.

Annals of the rheumatic diseases·2026
Same author

The clinical utility of telangiectasia quantification as markers of vascular disease progression in systemic sclerosis.

Rheumatology (Oxford, England)·2026
Same author

Assessing post-cold challenge recovery of thermography as a potential outcome measure in trials of SSc-related Raynaud's phenomenon.

Scientific reports·2026

This study reviews clinical trial designs for Raynaud

Area of Science:

  • Clinical trial methodology
  • Vascular medicine
  • Rheumatology

Background:

  • Raynaud's phenomenon (RP) is characterized by an exaggerated vasospastic response to cold or emotion.
  • Heterogeneity in RP necessitates careful consideration of clinical trial designs.
  • Current research focuses on optimizing trial methodologies for evaluating RP interventions.

Purpose of the Study:

  • To outline best practices for designing clinical trials investigating Raynaud's phenomenon.
  • To emphasize the importance of specific trial designs and outcome measures for RP research.
  • To guide future research in the development and evaluation of RP treatments.

Main Methods:

  • Recommends randomized, double-blind, placebo-controlled trials (parallel group or cross-over).
Keywords:
Raynaud’s phenomenonclinical trialsconnective tissue diseasesdigital ulcersgangrenemicrocirculationnailfold capillaroscopyrheumatic diseasessystemic sclerosisvasodilators

Related Experiment Videos

  • Highlights the utility of cross-over designs for early-phase trials, emphasizing the need for a wash-out period.
  • Discusses trial duration constraints, typically limited to a single winter season.
  • Mentions common outcome measures: frequency/duration of attacks and Raynaud's Condition Score.
  • Notes emerging interest in physiological endpoints like laser Doppler imaging for early trials.

    • Main Results:

    • Cross-over trials are suitable for RP, provided a wash-out period is included to mitigate carry-over effects.
    • Trial duration is often limited to 4 weeks or less per treatment arm due to seasonal constraints.
    • Established outcome measures like attack frequency and Raynaud's Condition Score remain widely used.
    • Physiological endpoints show promise for early-phase RP trials.

    Conclusions:

    • Rigorous trial designs, particularly cross-over studies with appropriate wash-out periods, are crucial for RP research.
    • Standardized outcome measures and exploration of physiological endpoints will enhance the evaluation of RP therapies.
    • Optimized trial methodologies are essential for advancing the understanding and treatment of Raynaud's phenomenon.